Physician profile
Mark G Bowles
NPI 1548260599
$5,382.58
in general payments reported to CMS, 2019-2025
46 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $568 · 2021: $665 · 2022: $651 · 2023: $712 · 2024: $861 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $566.77 | 2019-2020 | |
| Boston Scientific Corporation | $533.60 | 2019-2025 | Rezum Generator, Greenlight Xps, General - Erectile Dysfunction |
| Abbvie INC. | $524.57 | 2019-2025 | Lupron Depot, Botox |
| Sumitomo Pharma America, INC. | $368.56 | 2023-2025 | Gemtesa |
| Rochester Medical Corporation | $361.70 | 2019-2022 | |
| Astellas Pharma US INC | $333.16 | 2019-2024 | Myrbetriq, Veozah |
| Urogen Pharma, INC. | $271.10 | 2020-2025 | Jelmyto |
| C. R. Bard, INC. & Subsidiaries | $214.16 | 2019-2024 | Bard Urinary Drainage Bag |
| Urovant Sciences INC | $174.58 | 2021-2022 | |
| Tolmar, INC. | $150.01 | 2023-2024 | |
| Antares Pharma, INC. | $146.54 | 2019-2021 | |
| Neotract INC. | $142.63 | 2019 | |
| Endo Pharmaceuticals INC. | $115.99 | 2019-2021 | |
| Pfizer INC. | $111.56 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.07 | 2019-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $103.04 | 2019-2025 | Adstiladrin |
| Medtronic, INC. | $100.14 | 2022-2025 | Altaviva |
| Myovant Sciences INC. | $98.98 | 2021-2022 | |
| Janssen Biotech, INC. | $74.17 | 2019-2021 | |
| Blue Earth Diagnostics | $70.50 | 2022-2023 | |
| Telix Pharmaceuticals | $67.04 | 2025 | Illuccix |
| Tolmar Pharmaceuticals, INC. | $56.12 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $54.13 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $49.83 | 2021-2022 | |
| Abc Home Medical Supply, INC. | $49.52 | 2024-2025 | |
| Coloplast Corp | $43.71 | 2025 | |
| Procept Biorobotics Corporation | $42.68 | 2023 | Aquabeam Robotic System |
| Laborie Medical Technologies Corp. | $39.73 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Amgen INC. | $35.92 | 2021-2022 | |
| Teleflex LLC | $33.08 | 2021-2024 | Urolift |
| Calyxo, INC. | $32.64 | 2025 | Cvac Aspiration System |
| Inspire Medical Systems, INC. | $32.62 | 2024 | Inspire |
| Convatec INC. | $31.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $27.52 | 2023 | Opdivo |
| Clarus Therapeutics INC. | $24.07 | 2021 | |
| Axonics, INC. | $23.94 | 2024 | Bulkamid, Axonics |
| Millicent US INC | $23.90 | 2025 | Intrarosa |
| Sun Pharmaceutical Industries INC. | $22.13 | 2019 | |
| Agiliti Surgical, INC. | $19.87 | 2024 | Sonablate Hifu, Endocare Cryocare Cs System, Koelis Trinity Fusion Biopsy System |
| Mallinckrodt Enterprises LLC | $19.02 | 2019 | |
| 180 Medical, INC. | $18.78 | 2021 | |
| Ambu INC. | $13.26 | 2020 | |
| Allergan, INC. | $12.48 | 2021 | |
| Zyla Life Sciences, INC. | $12.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2022 | |
| Olympus America INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.